Arrowhead Pharmaceuticals(GB:0HI3)
$42.83-1.96 (-4.38%)
GB:0HI3
Arrowhead Pharmaceuticals ownership
$42.83
At close:-1.96 (-4.38%)
Arrowhead Pharmaceuticals (0HI3) Ownership - Who Owns Arrowhead Pharmaceuticals?
0 Followers
Arrowhead Pharmaceuticals (0HI3) Ownership Overview
- 3.64% Insiders
- 21.37% Mutual Funds
- 36.15% Other Institutional Investors
- 24.68% ETFs
- 14.16% Public Companies and Individual Investors
The ownership structure of Arrowhead Pharmaceuticals (GB:0HI3) stock is a mix of institutional, retail, and individual investors. Approximately 82.20% of the company’s stock is owned by Institutional Investors, 3.64% is owned by Insiders, and 14.16% is owned by Public Companies and Individual Investors.
Institutional holdings as of
The ownership structure of Arrowhead Pharmaceuticals (GB:0HI3) stock is a mix of institutional, retail, and individual investors. Approximately 82.20% of the company’s stock is owned by Institutional Investors, 3.64% is owned by Insiders, and 14.16% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Aug 19, 2026 | Adeoye Olukotun | $173,920 | |
| Aug 19, 2026 | Michael S. Perry | $1,012,680 | |
| Dec 18, 2025 | Christopher Richard Anzalone | $5,443,462 | |
| Dec 15, 2025 | Christopher Richard Anzalone | $12,348,802 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Graham Capital Management, L.p. | $279,435 | |
| Dec 31, 2025 | Entrypoint Capital, Llc | $329,360 | |
| Dec 31, 2025 | Bridgewater Associates, Lp | $3,981,142 | |
| Dec 31, 2025 | Platinum Investment Management | $5,940,842 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| BlackRock, Inc. | 15,140,840 | Institution | 10.71% | 648,482,177 |
| Ishares | 13,437,611 | Institution | 9.51% | 575,532,879 |
| Vanguard | 10,846,888 | Institution | 7.67% | 464,572,213 |
| Vanguard Index Funds | 10,698,015 | Institution | 7.57% | 458,195,982 |
| Spdr | 4,771,050 | Institution | 3.37% | 204,344,072 |
| Fidelity Mt. Vernon Street Trust | 3,966,507 | Institution | 2.81% | 169,885,495 |
| Christopher Richard Anzalone | 3,792,739 | Insider | 2.68% | 162,443,011 |
| David Gerald Greenspan | 2,523,500 | Institution | 1.79% | 108,081,505 |
| Invesco | 1,950,984 | Institution | 1.38% | 83,560,645 |
| Columbia Funds Series Trust I | 1,854,834 | Institution | 1.31% | 79,442,540 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 10,698,015 | Institution | 7.57% | 458,195,982 |
| Fidelity Mt. Vernon Street Trust | 3,966,507 | Institution | 2.81% | 169,885,495 |
| Columbia Funds Series Trust I | 1,854,834 | Institution | 1.31% | 79,442,540 |
| Fidelity Concord Street Trust | 1,387,160 | Institution | 0.98% | 59,412,063 |
| Alger Institutional Funds | 1,127,723 | Institution | 0.80% | 48,300,376 |
| Fidelity Salem Street Trust | 1,035,058 | Institution | 0.73% | 44,331,534 |
| Alger Funds | 702,434 | Institution | 0.50% | 30,085,248 |
| Manager Directed Portfolios | 572,008 | Institution | 0.40% | 24,499,103 |
| Fidelity Select Portfolios | 474,778 | Institution | 0.34% | 20,334,742 |
| Bridge Builder Trust | 443,402 | Institution | 0.31% | 18,990,908 |
FAQ
Who Owns Arrowhead Pharmaceuticals (GB:0HI3)?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 82.20% of the company's stock is held by institutional investors, 3.64% is held by insiders, and 14.16% is held by public companies and individual investors.
What percentage of Arrowhead Pharmaceuticals (GB:0HI3) stock is held by institutional investors?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 82.20% of Arrowhead Pharmaceuticals (GB:0HI3) stock is held by institutional investors: 21.37% by mutual funds, 24.68% by ETFs and 36.15% by other institutional investors.
What percentage of Arrowhead Pharmaceuticals (GB:0HI3) stock is held by retail investors?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 14.16% of Arrowhead Pharmaceuticals (GB:0HI3) stock is held by public companies and individual investors.
Who owns the most shares of Arrowhead Pharmaceuticals (GB:0HI3)?
BlackRock, Inc. owns the most shares of Arrowhead Pharmaceuticals (GB:0HI3).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.

